

# Contents

<b>Section 1</b>	<b>The Basics</b>	<b>1</b>
Chapter 1	A General Framework for Regulatory Intelligence in Medical Product Research and Development <i>Chris Whalley</i>	3
Chapter 2	Paving Your Path in Regulatory Intelligence: Skill Development and Transition Strategies <i>Brandy Proctor, MS</i>	11
Chapter 3	Establishing a Robust Regulatory Intelligence Function <i>Joseph M. Thomas, PhD; Tony E. Catka, PhD; Patrick Frey</i>	19
Chapter 4	Scoping Regulatory Intelligence Deliverables <i>Alex May, MS</i>	27
Chapter 5	Establishing Key Performance Indicators to Advocate for a Dedicated Regulatory Policy and Intelligence Function <i>Patterson Shafer</i>	31
Chapter 6	Homegrown Regulatory Intelligence Tools <i>John Joines, RPh; Sean Schofield, PharmD, MS</i>	39
Chapter 7	Regulatory Intelligence Tools <i>Sam Kay, MPharm; Charity-Anne Metz Schuller, PharmD, MSCR, RAC-US</i>	43
<b>Section 2</b>	<b>Deliverables</b>	<b>51</b>
Chapter 8	Monitoring and Surveillance <i>Elayne Kimmett, MBA, CQA, RAC-Global; Joseph M. Thomas, PhD</i>	53
Chapter 9	FOIA and Access to Information <i>Rachel Cuccias, MS</i>	59
Chapter 10	Partnering With SMEs on Impact Analysis <i>Eliza Shearer; Stephanie Sabatino Kelly, JD, MS</i>	69
Chapter 11	Regulatory Intelligence Distribution and Communication <i>Lieselotte L. Bloss, DVM; Chelsea Miller, MA</i>	73
Chapter 12	What Is Regulatory Research, and Why Is It Important? <i>Tom Dillane, MSc; Kieran Maher, MSc; João Duarte, MSc, MPharm, FTOPRA, FRAPS</i>	77

## Regulatory Intelligence Reimagined

Chapter 13	Discovering Regulatory Intelligence Within Your Records .....	85
	<i>Patterson Shafer; Purba Ganguly, MSc, CPbT</i>	
Chapter 14	Regulatory Intelligence: How to Measure Success.....	93
	<i>Linda Bowen, MS, RAC-CAN, RAC-EU, RAC-US, FRAPS; James Lindsay Cobbs, RPh; Purba Ganguly, MSc, CPbT</i>	
Chapter 15	Monitoring, Analyzing, and Interpreting Regulatory Trends .....	97
	<i>João Duarte, MSc, MPharm, FTOPRA, FRAPS; Kirsten Messmer, PhD, RAC-US; Marco Rafael, PharmD, MBA</i>	

## Section 3 Supporting Health Authority Interactions ..... 105

Chapter 16	Creating More Strategic Submissions Through FDA Division and Reviewer Profiling .....	107
	<i>Virginia Cox, JD; Lindsay Simon, RAC-Drugs</i>	
Chapter 17	Creating More Effective Health Authority Meetings Through Participant Profiling .....	111
	<i>Michelle Zucatti, MHA</i>	
Chapter 18	Public Sources of Regulatory Precedent.....	117
	<i>Linda Bowen, MS, RAC-CAN, RAC-EU, RAC-US, FRAPS; Robert F. Kester, MS</i>	
Chapter 19	Applications of Regulatory Precedent Research.....	131
	<i>Anusha Kesireddy, PhD, MS, BPharm; Hannah Hapner Hogan, MSc; Thomas Stover, PhD, MBA</i>	
Chapter 20	Supporting Device Development and Approval Pathway Strategies.....	137
	<i>Andrew C. Wingen, MS, RAC-Global; Kenneth G. Butz, MS</i>	
Chapter 21	Regulatory Intelligence's Role in Preparing the Due Diligence Team .....	143
	<i>Kirsten Messmer, PhD, RAC-US</i>	

## Section 4 The Policy Side..... 155

Chapter 22	Introduction to Regulatory Policy.....	157
	<i>Joshua S. Silverstein, PhD; Alex May, MS</i>	
Chapter 23	Leveraging Collective Influence in Regulatory Policy: The Value of Engaging With External Stakeholders .....	161
	<i>Pedro Franco, PhD, PharmD, MBA, MSc; Andrew C. Wingen, MS, RAC-Global; Raya D. Zerger, MT(ASCP)SBB</i>	
Chapter 24	Best Practices in Commenting.....	167
	<i>Soufiane Dib, PharmD; Emily Huddle, BSc; Joshua S. Silverstein, PhD</i>	
Chapter 25	Development of White Papers.....	175
	<i>Charity-Anne Metz Schuller, PharmD, MSCR, RAC-US</i>	

## Section 5 The Intersection of Artificial Intelligence and Regulatory Intelligence..... 179

Chapter 26	Artificial Intelligence and Its Potential in Regulatory Intelligence .....	181
	<i>Amin Osmani, MSc, MSc</i>	
Chapter 27	Use of Artificial Intelligence/Machine Learning to Enhance Regulatory Intelligence Analysis Capabilities .....	191
	<i>Aleksandr Merenkov, PharmD, MS, MBA, RAC-Drugs; Jeff MacDonald, PharmD, RPh</i>	
Chapter 28	Embracing the Digital Revolution: Applying AI and ML Technology Within the Regulatory Intelligence Function.....	207
	<i>Rudy Fuentes, PhD, RAC-US; Amra Racic, MBA</i>	

## Index ..... 213

## My RI Journey

Ambiguity as a Compass: Building a Career Without a Map .....	17
<i>Alex May, MS</i>	
Turning Global Regulatory Complexity Into Innovations for Patients .....	37
<i>Jeff MacDonald, PharmD, RPh</i>	
A Career Built on Curiosity, Compliance, and Continuous Learning.....	67
<i>Elayne Kimmitt, MBA, CQA, RAC-Global</i>	
Regulatory Intelligence: The Bridge Between Discovery and Delivery .....	83
<i>Charity-Anne Metz Schuller, PharmD, MSCR, RAC-US</i>	
Finding My Way: Serendipity, Science, and Staying Curious .....	103
<i>Linda Bowen, MS, RAC-CAN, RAC-EU, RAC-US, FRAPS</i>	
Regulatory Intelligence: It's in My Plasma.....	129
<i>Raya D. Zerger, MT(ASCP)SBB</i>	
Stay Curious and Learn as You Go .....	153
<i>Kirsten Messmer, PhD, RAC-US</i>	
Be Open to Discomfort and Success May Follow .....	173
<i>Andrew C. Wingen, MS, RAC-Global</i>	
Chance, a Few Risks, and No Regrets .....	205
<i>Joshua S. Silverstein, PhD</i>	

## Figures

Figure 1-1. Different Perspectives on Regulatory Intelligence.....	3
Figure 1-2. Common Components of Highly Effective RI Programs.....	5
Figure 1-3. RI Roles in a Small Organization .....	6
Figure 1-4. RI Roles in a Large Organization .....	6
Figure 1-5. Processes Within Each Component of an RI Program.....	7
Figure 3-1. Five Key Benefits of RI to a Biopharmaceutical Company.....	19
Figure 5-1. Metrics Hierarchy .....	32
Figure 6-1. Regulatory Tool Development Process.....	40
Figure 13-1. Process Improvement – Manual Classification to AI-Enabled Search of Regulatory Assets .....	89
Figure 13-2. Regulatory Intelligence Input to the Product Change Agenda.....	90
Figure 21-1. Comparison of Due Diligence in the Acquisition of a Pharmaceutical Asset Compared to a House Purchase .....	144
Figure 26-1. Large Language Models (LLMs) in Relation to Other AI Concepts.....	183
Figure 26-2. The RI Workflow and Potential Areas Where AI Can Support the Workflow.....	184
Figure 28-1. AI-Enabled RI Workflow With Human-in-the-Loop (HITL) Gates .....	208

## Tables

Table 3-1. Organization and Roles by Company Size.....	21
Table 3-2. Scope and Coverage of RI Content by Company Size .....	22
Table 3-3. Categories and Examples of External Networks and Their Value to RI.....	24
Table 4-1. Core Activities of RI .....	27
Table 4-2. RI Deliverables by Product Lifecycle Phase .....	28
Table 5-1. Sample Objectives and KPIs.....	34
Table 11-1. The Case for Effective Communications of RI .....	74
Table 13-1. Sample Regulatory Metrics Dictionary.....	89
Table 16-1. Framing Your Questions .....	109
Table 17-1. Key Profile Elements for Health Authority Meeting Participants .....	112

**Regulatory Intelligence Reimagined**

Table 19-1. Sources of Regulatory Precedent.....132  
Table 25-1. Regulatory Authority White Paper Examples.....177  
Table 25-2. Other White Paper Resources.....177  
Table 27-1. Key AI Vendor Capabilities for Evaluation.....197  
Table 27-2. Phased Approach for Sustainable and Strategic AI Adoption .....203  
Table 27-3. AI Adoption in RI Checklist .....203  
Table 28-1. Guardrails Control Catalog.....208  
Table 28-2. Mapping Policy and Standards to Implement Controls.....209  
Table 28-3. Competitive Landscape Questions and AI Support .....210